Sorry Novo: Sanofi wins Ablynx over with $4.8B buyout bid, bagging nanobody platform tech
Sanofi $SNY has struck again — this time acquiring Ablynx, the Belgian biotech that has turned down two previous bids by Novo Nordisk, for $4.8 billion.
The French drugmaker agreed to pay a whopping $55.81 per share to swallow Ablynx’s antibody technology, almost 50% higher than Novo’s $33.60 per share offer. Investors clearly liked how Ablynx held out, sending its shares $ABLX up 17% in premarket trading.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters